Creating antibodies to study bat immune responses
Official title: DEVELOPMENT OF RABBITMONOCLONAL ANTIBODIES FOR INDIANFLYING FOX (BAT) BIOMARKERS
Funded at Avantgen, INC. · NIH-11219378 · Data updated 2026-11-12
This study is all about creating special tools to help scientists understand how bats fight off viruses, which could help keep people healthy by preventing diseases that come from bats.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Avantgen, INC. NIH-funded |
| Lab location | 1 site (San Diego, United States) |
| Project start | September 1, 2024 |
| Project end | August 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $592,751 |
| NIH project number | 75N93024C00039-0-9999-1 |
| Project ID | NIH-11219378 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research would include researchers and scientists studying bat biology or zoonotic diseases.
✕Less likely to help
Patients who are not involved in bat research or who do not have an interest in zoonotic diseases may not benefit from this research.
What this research studies
This research focuses on developing specific rabbit monoclonal antibodies that target immune markers in bats. The project aims to produce and characterize these antibodies, which will then be used to create assays for detecting bat antigens in various samples. By understanding how bats respond to viral infections, this research could provide insights that are crucial for public health and disease prevention. The methodology includes advanced techniques like ELISA and flow cytometry to analyze immune responses.
Why it matters
Potential benefit: If successful, this research could enhance our understanding of bat immune responses, which may inform strategies for managing zoonotic diseases.
How similar studies have gone: Other research has shown success in using monoclonal antibodies for studying immune responses in various species, indicating a promising approach.
Where this research is happening
-
Avantgen, INC.
San Diego, United States Active
Researchers
- Principal investigator: Fan, Xiaomin — Avantgen, INC.
- Study coordinator: Fan, Xiaomin
Related research
Other NIH-funded projects on the same topics.
-
New treatment approach for myelodysplastic syndrome and acute myeloid leukemia
This project aims to develop a new antibody-based therapy to help people with MDS or AML, especially older or frail patients who cannot tolerate high-dose chemotherapy.
-
New treatment options for myelodysplastic syndrome and acute myeloid leukemia
This study is exploring new treatment options for people with myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) by looking at their genetic makeup and developing targeted therapies that could help improve their health.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.